

# CITATION REPORT

List of articles citing

**Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study**

**DOI: 10.1186/s13075-020-02282-0**

**Arthritis Research and Therapy, 2020, 22, 191.**

**Source:** <https://exaly.com/paper-pdf/76308322/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
15	[Therapeutic de-escalation in systemic lupus erythematosus in remission]. <i>Revue De Medecine Interne</i> , <b>2020</b> , 41, 795-799	0.1	0
14	Hydroxychloroquine. <i>Reactions Weekly</i> , <b>2020</b> , 1831, 146-146	0	
13	COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. <i>Translational Research</i> , <b>2021</b> , 232, 13-36	11	26
12	COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases. <i>Rheumatology International</i> , <b>2021</b> , 41, 257-273	3.6	0
11	Initial hydroxychloroquine monotherapy in systemic lupus erythematosus: report of three cases. <i>Modern Rheumatology Case Reports</i> , <b>2021</b> , 5, 259-264	0.4	
10	Hydroxychloroquine in systemic and autoimmune diseases: Where are we now?. <i>Joint Bone Spine</i> , <b>2021</b> , 88, 105143	2.9	4
9	Hydroxychloroquine dans les maladies systémiques et auto-immunes : où en sommes-nous ?. <i>Revue Du Rhumatisme (Edition Francaise)</i> , <b>2021</b> , 88, 346-353	0.1	
8	Hydroxychloroquine and lupus flare: a good drug, but we need to do better.. <i>Annals of the Rheumatic Diseases</i> , <b>2022</b> ,	2.4	0
7	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	4
6	Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2022</b> , 14, 1759720X211073001	3.8	5
5	Hydroxychloroquine on the Pulmonary Vascular Diseases in Interstitial Lung Disease: Immunologic Effects, and Virus Interplay. <i>Biomedicines</i> , <b>2022</b> , 10, 1290	4.8	
4	Outcomes following antimalarial withdrawal in patients with quiescent systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , <b>2022</b> , 55, 152046	5.3	
3	Why lupus patients discontinue antimalarials in real life: A 50 years-experience from a reference centre. <i>Lupus</i> , 096120332211156	2.6	0
2	Envisager la déescalade thérapeutique au cours du Lupus Erythémateux Systémique : du concept de T2 T à celui de T2U. <b>2022</b> ,		0
1	Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus. <b>2023</b> , 10, e000841		0